Illumina (ILMN)
$94.30
0.25 (0.27%)
ILMN Stock Quote Delayed 30 Minutes
10 Best “Strong Buy” Stocks — EQM DAL BITA and more
This week, these ten stocks, all currently earning A's ("strong buy") on Portfolio Grader, have the best year-to-date performance.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$95.76
Market Cap
14.90B
PE Ratio
-12.26
EPS
-7.6918
Volume (Avg. Vol.)
1.82M
Day's Range
$93.21 - $96.88
52-Week Range
$91.92 - $156.66
Dividend & Yield
N/A (N/A)
ILMN Stock Predictions, Articles, and Illumina News
ILMN Stock – The New Illumina Human Genome Machine Is a Game Changer
Illumina says it has developed a DNA sequencing machine that can scan a genome for under $1,000, sending ILMN stock higher.
Bull’s Eye Report: Illumina (ILMN)
ILMN has been making higher highs and higher lows since early February, and right now is at a great entry point.
So Your DNA Can’t Be Patented … Now What?
The Supreme Court recently ruled that identifying genes is not patentable ... which is both good and bad news for DNA-mapping companies.
Ride This Biotech’s Powerful Bull Trend
Illumina jumped to a 20-month high and is under heavy accumulation.
Top 6 Stocks to Buy for May
As we enter a period of historical seasonal weakness, this month's list contains stocks that are in powerful bull markets.
Life Science Stocks Aren’t Completely Hopeless, But …
A government sequestration won't rip into all life sciences stocks equally, but its presence will be felt -- a grim possibility for an already-struggling industry.
Hedge Fund Darlings That Look Like ‘Sells’
Of the top 50 stocks held by hedge funds, these 14 are rated a “strong sell” by my technical parameters.
Euro, Mexico, Oh No! — Monday’s IP Market Recap
Bribery accusations hampering Wal-Mart and worries in Europe in China weighed on markets in Monday trading.
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.
Nasdaq’s Big Names Romp — Thursday’s IP Market Recap
Google (GOOG) surged before Thursday's earnings report, then announced an 'effective' stock split. Meanwhile, Starbucks hit an all-time high.
Analysts Run the Apple Asylum — Tuesday’s IP Market Recap
Price targets keep climbing to the moon: $715, $910 -- even $1,001.
Why Illumina’s Future Remains Bright
Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects.
Illumina Sparks Mean Gene Rally — Wednesday’s IP Market Recap
A hostile offer from Roche warms investors' hearts.
Roche’s Hostile Bid for Illumina Could Reach $60 Per Share
Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done.
5 Earnings Predictions That Will Impact Your Portfolio Now
These two companies look like they will release strong, estimate-beating results, but these three others may not fare as well.
Illumina Shares Take a Tumble
The biotech's stock hits the skids after the company warns revenue will take a hit.
